Biogen Inc (BIIB)

Mar 18, 2025, 2:39 PM EDT - 4 days ago

Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)

Mar 11, 2025, 7:30 AM EDT - 12 days ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Mar 10, 2025, 6:02 PM EDT - 12 days ago

Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)

Mar 3, 2025, 6:29 PM EST - 19 days ago

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)

Feb 28, 2025, 7:55 AM EST - 23 days ago

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

Feb 18, 2025, 8:46 AM EST - 4 weeks ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

STOK

Feb 18, 2025, 8:00 AM EST - 4 weeks ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

STOK

Feb 15, 2025, 5:55 AM EST - 5 weeks ago

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 13, 2025, 2:30 PM EST - 5 weeks ago

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

Feb 13, 2025, 9:03 AM EST - 5 weeks ago

Biogen Analysts Lower Their Forecasts After Q4 Results

Feb 12, 2025, 3:54 PM EST - 5 weeks ago

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook

Feb 12, 2025, 12:41 PM EST - 5 weeks ago

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:48 AM EST - 5 weeks ago

Biogen's stock hit by soft guidance and a decline in sales of MS drugs

MS

Feb 12, 2025, 6:50 AM EST - 5 weeks ago

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Feb 12, 2025, 6:47 AM EST - 5 weeks ago

Drugmaker Biogen forecasts 2025 profit below expectations

Feb 12, 2025, 3:22 AM EST - 5 weeks ago

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 31, 2025, 6:46 AM EST - 7 weeks ago

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Jan 31, 2025, 6:30 AM EST - 7 weeks ago

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Jan 27, 2025, 9:28 AM EST - 7 weeks ago

Sage rejects Biogen's $469 million takeover offer

Jan 26, 2025, 6:38 PM EST - 7 weeks ago

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

Jan 26, 2025, 6:33 PM EST - 7 weeks ago

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Jan 23, 2025, 7:30 AM EST - 2 months ago

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

Jan 23, 2025, 4:05 AM EST - 2 months ago

Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth

Jan 15, 2025, 9:20 AM EST - 2 months ago

Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Jan 14, 2025, 6:01 PM EST - 2 months ago

Biogen CEO sees no burning need for more acquisitions

Jan 13, 2025, 7:05 PM EST - 2 months ago

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Jan 13, 2025, 10:40 AM EST - 2 months ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

SAGE

Jan 13, 2025, 7:24 AM EST - 2 months ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

SAGE

Jan 10, 2025, 6:49 PM EST - 2 months ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

SAGE

Jan 10, 2025, 6:37 PM EST - 2 months ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

Jan 8, 2025, 8:00 AM EST - 2 months ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

AGIO

Dec 30, 2024, 1:37 PM EST - 2 months ago

Beaten Down Biogen Stock Looks Attractive At Current Levels

Dec 27, 2024, 12:22 PM EST - 3 months ago

Investing pros think these stock-market losers are set to rebound in 2025

CE DG DLTR EL ENPH HUM INTC

Dec 23, 2024, 3:45 PM EST - 3 months ago

Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman

LLY VRTX

Dec 12, 2024, 12:52 PM EST - 3 months ago

Private Medicare plans must cover Biogen's ALS drug, US agency says

Dec 9, 2024, 1:44 PM EST - 3 months ago

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Dec 5, 2024, 8:30 AM EST - 3 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

PRAX STOK WGS

Dec 3, 2024, 12:15 PM EST - 3 months ago

Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Dec 3, 2024, 9:57 AM EST - 3 months ago

Biogen expects steady growth for Alzheimer's drug Leqembi in near term

Nov 20, 2024, 1:32 PM EST - 4 months ago

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Nov 19, 2024, 1:00 AM EST - 4 months ago

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Nov 18, 2024, 1:18 PM EST - 4 months ago

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Nov 18, 2024, 7:00 AM EST - 4 months ago

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

Nov 14, 2024, 1:53 PM EST - 4 months ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector

AMGN LLY PFE XLV

Nov 14, 2024, 1:21 PM EST - 4 months ago

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

Nov 14, 2024, 11:17 AM EST - 4 months ago

EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen

Oct 31, 2024, 5:42 PM EDT - 5 months ago

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31, 2024, 1:28 PM EDT - 5 months ago

Biogen Analysts Slash Their Forecasts After Q3 Results

Oct 30, 2024, 7:30 PM EDT - 5 months ago

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Oct 30, 2024, 12:49 PM EDT - 5 months ago

Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript